Merck & Co. , Inc. operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Merck & Co. with three other
companies in this sector in UNITED STATES :
sales of $45.80 billion
of which 100%
was pharmaceutical products),
Bristol-Myers Squibb Company
of which 28%
was Prioritized Brands-Revlimid), and
of which 26%
During the second
quarter of 2021, sales at Merck & Co. totalled
an increase of 4.9%
from the $10.87 billion in sales at the company during the second quarter of 2020.
During the first two
quarters of 2021, sales totalled $22.03 billion, which is
than through the first two quarters of 2020.
Merck & Co. reported sales of $47.99 billion
December of 2020.
increase of 2.5%
versus 2019, when the company's sales were $46.84 billion.
Sales at Merck & Co. have increased during each of the previous five years
(and since 2015, sales have increased a total of 22%).
Sales of Animal Healthcare saw an increase
that was more than double the company's growth rate: sales were up
7.1% in 2020, from
$4.39 billion to $4.70 billion.
Not all segments of Merck & Co. experienced an increase in sales in 2020:
sales of All Other fell 86.9% to $23.00 million.
(However, this segment's sales were only a very small portion of the company's overall sales).
Merck & Co. also experienced decreases in sales in
Unallocated (down 52.6% to $247.00 million)